PTGER3 and myeloid sarcoma: Notably, PGE2–EP3 signalling does not seem to contribute to MS pathology, as MS-related murine models have shown that EP3 is not present in MS lesions, no correlations are found between EP3 mRNA expression and EAE severity and EAE clinical signs are unaffected in EP3 KO EAE mice in vivo [39, 50].